Healthcare Industry News: BioVentrix
News Release - August 18, 2008
Kevin Van Bladel Joins BioVentrix as Vice President of Research and Development
SAN RAMON, Calif.--(HSMN NewsFeed)--CHF Technologies, Inc., d/b/a BioVentrix, San Ramon, California, announced today that Kevin Van Bladel has joined the company as Vice President of Research and Development.Mr. Van Bladel was formerly Vice President of Engineering, Manufacturing and Quality for Aspara Medical where he guided the Research and Development team from product concept through clinical trials. With 15 years of experience in the medical device industry, Mr. Van Bladel has a proven track record, particularly with successfully bringing innovative products to market.
“Kevin is an exceptionally gifted scientist and executive. We are pleased he has decided to join the BioVentrix team where he will help us enhance our product offering and better serve the heart failure population,” said Ken Miller, BioVentrix President and CEO.
Mr. Van Bladel will lead the Research and Development efforts for PliCath HF™ as BioVentrix prepares for anticipated European clinical trials in early 2009. PliCath HF is a device developed to perform Epicardial Catheter-based Ventricular Reconstruction (ECVR). ECVR is a procedure that reduces the size of the heart, creating a more effective pump in patients with heart failure.
“I feel fortunate to have the opportunity to work for a company that is addressing this devastating disease,” said Van Bladel. “Heart failure affects millions of people around the world. BioVentrix has a solid pipeline of products as well as a dedicated staff and leadership to achieve market success.”
Mr. Van Bladel received his Bachelor of Science in Physics from California Institute of Technology in Pasadena, California.
About BioVentrix
BioVentrix is a private corporation based in San Ramon, California. Its mission is to improve and expand on the surgical treatment of heart failure by left ventricular reconstruction, primarily through the development of less invasive approaches, and ultimately, catheter-based procedures. BioVentrix’s Scientific Advisory Board and associated physicians include some of the country’s leading surgeons and cardiologists. For more information, please visit www.BioVentrix.com.
Source: BioVentrix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
